[A15-50] Nivolumab - Addendum to Commission A15-27
Last updated 07.01.2016
Commission awarded on 25.11.2015 by the Federal Joint Committee (G-BA).
Skin and hair, Cancer
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-40||Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)||Commission completed|
|A15-27||Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|